Immune-mediated hepatitis
Clinical trials for Immune-mediated hepatitis explained in plain language.
Never miss a new study
Get alerted when new Immune-mediated hepatitis trials appear
Sign up with your email to follow new studies for Immune-mediated hepatitis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to tame liver side effects of cancer immunotherapy
Disease control Recruiting nowThis study tests whether combining mycophenolate mofetil (MMF) with prednisone can better treat liver inflammation caused by checkpoint inhibitor cancer drugs. The trial includes adults with moderate to severe immune-related hepatitis who need to pause their cancer therapy. The m…
Matched conditions: IMMUNE-MEDIATED HEPATITIS
Phase 2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a Low-Dose steroid tame Immunotherapy's liver side effect?
Disease control Recruiting nowThis study looks at whether low-dose prednisolone (a steroid) can safely treat liver inflammation (hepatitis) caused by immune checkpoint inhibitors in cancer patients. Researchers will enroll 63 adults with grade 2 or 3 immune-related hepatitis and give them 0.5-1 mg/kg of predn…
Matched conditions: IMMUNE-MEDIATED HEPATITIS
Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 26, 2026 16:53 UTC
-
New study aims to uncover hidden liver risks of immunotherapy
Knowledge-focused Recruiting nowThis study observes 160 cancer patients to understand why some develop liver injury from checkpoint inhibitor drugs. Researchers will track blood markers and genetic factors to identify who is at risk. No new treatment is tested; the goal is to improve diagnosis and monitoring.
Matched conditions: IMMUNE-MEDIATED HEPATITIS
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Blood test could spot Immunotherapy-Linked liver damage
Knowledge-focused Recruiting nowThis study aims to identify specific blood markers that can distinguish hepatitis caused by immune checkpoint inhibitors from other types of autoimmune hepatitis. Researchers will collect blood samples and liver tissue from 60 adults receiving immunotherapy. The goal is to improv…
Matched conditions: IMMUNE-MEDIATED HEPATITIS
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC